News und Analysen
VALBIOTIS Releases Its 2020 Annual Results
Regulatory News:
2020 highlights and results
-
Global strategic partnership with Nestlé Health Science for the development and marketing of TOTUM-63, a plant-based active substance with
Eyenovia Announces Publication of MIST Pivotal Studies Demonstrating the Efficacy and Safety of its MAP™ Fixed-Combination Tropicamide-Phenylephrine Product for Mydriasis
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today
Navidea Biopharmaceuticals to Host Fourth Quarter 2020 Earnings Conference Call and Corporate Update
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Der erste Patient schließt in Phase IIb die digitale Einwilligung mit dem Veeva Clinical Network ab
Veeva Systems (NYSE: VEEV) gab heute bekannt, dass Veeva eConsent, eine MyVeeva for Patients-Anwendung, die auf dem Veeva Clinical Network basiert, von seinem ersten Patienten eine elektronische
IMV Inc. Announces Fourth Quarter and Full Year 2020 Financial and Operational Results
IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational
Survey: Provider Burnout and Disengagement Seen as Most Potentially Disruptive Forces in Healthcare
The most potentially disruptive forces facing hospitals and health systems in the next three years are provider burnout, disengagement, and resulting shortages among healthcare professionals
Simulations Plus Forms Scientific Advisory Board for RENAsym Consortium
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services (DSS)
Premier Inc. to Participate in KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum on March 23, 2021
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, announced today that members of its management team are scheduled to present at the KeyBanc Capital Markets Virtual Life
EUROIMMUN bringt ultraschnelles automatisiertes Mikroskop und intelligente Software für moderne Befunderhebung am Bildschirm auf den Markt
EUROIMMUN, a PerkinElmer, Inc. company, gab heute die Markteinführung des kompakten Immunfluoreszenz-Mikroskops EUROPattern Microscope Live (EPML) mit EUROLabOffice 4.0 (ELO 4.0), der vierten
Humana Introduces CenterWell as the New Brand for a Range of Its Payer-Agnostic Health Care Services Offerings
Leading health and well-being company Humana Inc. (NYSE: HUM) announced today a new brand – CenterWell – to describe and connect a range of the company’s payer-agnostic health care services
First Patient Completes Digital Consent with Veeva Clinical Network in Phase 2b Study
Veeva Systems (NYSE: VEEV) today announced that Veeva eConsent, a MyVeeva for Patients application built on Veeva Clinical Network, had its first patient complete an electronic consent for an early
Newron Announces 2020 Financial Results and Provides Outlook For 2021
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
First Patient Completes Digital Consent with Veeva Clinical Network in Phase 2b Study
Veeva Systems (NYSE: VEEV) today announced that Veeva eConsent, a MyVeeva for Patients application built on Veeva Clinical Network, had its first patient complete an electronic consent for an early
Savara Announces Closing of $130 Million Public Offering Following Full Exercise of Underwriters’ Option
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the closing of its previously announced underwritten public offering of 57,479,978 shares of its common stock, including
Agilent Announces the 8697 Headspace Sampler with Integrated Intelligence
Agilent Technologies Inc. (NYSE: A) today introduced the Agilent 8697 Headspace Sampler, the first headspace sampler with integrated gas chromatography communication. It marks the expansion of
Newron Signs Agreement for Starting a Potentially Pivotal Study With Safinamide in Parkinson’s Disease Patients
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
Aurinia Announces Positive Cost-Effectiveness Assessment of LUPKYNIS™ (voclosporin) in Latest ICER Draft Evidence Report
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today announced a favorable assessment regarding the cost-effectiveness and value of LUPKYNIS™ (voclosporin), based
Chemed Corporation to Present at the Oppenheimer 31st Annual Healthcare Conference
Chemed Corporation (NYSE:CHE) today announced that it will deliver a virtual presentation at the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021, at approximately 8:40
Sensorion to Present at Two Conferences on March 16th 2021
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
VALBIOTIS: Kalender der Finanzkommunikation für 2021
Pflichtmitteilung:
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / qualifiziert für PEA/SME), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur
Illumina and Harvard Pilgrim Health Care Real-World Evidence Study Demonstrates Cost-Effectiveness of Offering NIPT to All Pregnant Women
Illumina, Inc. (NASDAQ: ILMN), along with researchers at the University of Colorado and Harvard Pilgrim Health Care (HPHC), reported study results evaluating the impact of an innovative
VALBIOTIS: 2021 Financial Communication Calendar
Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / eligible for the PEA/SME), a Research & Development company committed to scientific innovation for preventing and combating
Savara Announces Pricing of Public Offering of Common Stock
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the pricing of an underwritten public offering of 45,785,828 shares of its common stock at a price to the public of $1.45
Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared
The Israel Ministry of Health (MoH), Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced real-world evidence demonstrating dramatically lower incidence rates of COVID-19 disease